Well done, Mina M. Benjamin Mehanni, MD, MSc. Thank you Cardiovascular Business for the great coverage of our publication. Diagnostics MDPI #AI #TAVR

The SCCT Knowledge Lab | Demystifying billing, coding & the CCT revenue cycle is taking place NOW! 🏃‍♀️🏃‍♂️ to join us for this free webinar: scct.org/events/EventDe…

Ahmad M. Slim Mark Rabbat MD Kanae Mukai

How is the huge #cardiovascular benefit of Icosapent ethy ( #IPE ) in REDUCE-IT justified??🤔🤔
👉Because it results in early and sustained improvement of #coronary physiology: EVAPORATE-FFRCT
buff.ly/419doo3
#Atherosclerosis #triglycerides #remnant #cholesterol #omega -3

Heart disease is the leading cause of death. Inadequate cardiac CT reimbursement limits access to life saving, quality patient care. Together, with the help of #Congressional and #CMS leaders, we can accomplish this. #advocacy #yesCCT #healthequity Rep. Mike Kelly Rep. Ted Lieu

Patient care is on the line! SCCT is strongly urging all members to submit comments to CMSGov by Sept 11 to show how inadequate reimbursement for CCTA could be devastating. Let's fight for quality patient care! #patientcare #CCTA #CMS @MGRabbatMD

ow.ly/EP4c50PGwon

SCCT is sounding the alarm! Submit your #comments to CMSGov by Sept 11 to show how inadequate #CT reimbursement will hurt quality #patientcare .

Make your voice heard:ow.ly/tBPy50PBvA0

In a first ever study to assess drug effect by FFR-CT, we demonstrate that Icosapent ethyl improves coronary physiology in the EVAPORATE trial. Thank you Matthew Budoff MD Dr. Deepak L. Bhatt Mark Rabbat MD for the mentorship Heart_SCCT FiRST - SCCT

EVAPORATE-FFRCT paper: academic.oup.com/ehjcimaging/ar…

Host Praveen Ranganath is joined by Mark Rabbat MD, professor of cardiology from Loyola University, to discuss his EVAPORATE-FFRCT publication & the relationship between coronary atherosclerosis, coronary physiology, icosapent ethyl, & CT imaging biomarkers.
donutofdestiny.buzzsprout.com/874432/1341779…

SCCT is strongly urging all members to act NOW: submit comments to CMSGov by Sept 11 highlighting how failure to reimburse CCTA harms #patientcare . Don't miss your chance to make your voice heard!

Learn more: ow.ly/VjbK50PskK0

Excellent talk 👏on “Economics of Cardiac CT and Precise Trial” by ⁦Mark Rabbat MD⁩ -CCTA+FFR pathway adoption led to increase in 1.Increase in High value interventions in the right patient and 2. Decrease in low value diagnostic only procedures” #YesCCT ⁦Heart_SCCT⁩

What a way to kick of #SCCT2023 ! @kunaemukai discusses #YesCCT in community hospitals.

Ronald Karlsberg MD Mark Rabbat MD Patrycja Galazka Eric Williamson Brian with the Good Dictations

New data from EVAPORATE: In statin-treated patients with CAD and elevated triglycerides, icosapent ethyl benefited coronary physiology as assessed by CT-derived FFR vs. placebo @loyolahealth European Society of Cardiology Journals Mark Rabbat MD Dr. Deepak L. Bhatt Matthew Budoff MD #cardiotwitter healio.com/news/cardiolog…

Promising news! Latest study shows icosapent ethyl can significantly improve distal segment FFRCT compared to placebo.
#cardiology #research #IPE #hearthealth Dr. Deepak L. Bhatt
academic.oup.com/ehjcimaging/ad…

Want to learn more about interpretation, reporting and clinical decision-making utilizing FFRCT in clinical practice? Join us on Wed. April 26 for the Clinical Application of FFR-CT workshop. Mark Rabbat MD

Learn more: ow.ly/oqJs50NPneS